ALERT! Warning: your browser isn't supported. Please install a modern one, like Firefox, Opera, Safari, Chrome or the latest Internet Explorer. Thank you!
Specifications Manual for Joint Commission National Quality Measures (v2016A)
Home » Appendix HTJC

Release Notes:
Appendix HTJC
Version 2016A

Appendix H

Miscellaneous Tables

Table 2.1 VTE Prophylaxis Inclusion Table

VTE Prophylaxis Inclusion/Synonyms
Coumadin/Warfarin Coumadin
Jantoven
Warfarin
Warfarin Sodium
Factor Xa Inhibitor Arixtra
Fondaparinux sodium
Oral Factor Xa Inhibitor Apixaban 1
Edoxaban 3
Eliquis 1
Rivaroxaban 2
Savaysa 3
Xarelto 2
Low Dose Unfractionated Heparin (LDUH)
- Include only Heparin given by the subcutaneous (SQ, Subcu, SC, SubQ) route
HEP
Heparin
Heparin Na
Heparin Sod
Heparin Sodium
Heparin Sodium Inj.
Heparin Sodium Inj. Pork
Heparin Subcu/SQ/SC/SubQ
Low Molecular Weight Heparin (LMWH) Dalteparin
Enoxaparin
Fragmin
Innohep
Lovenox
Tinzaparin
Intermittent Pneumatic Compression Device (IPC) AE pumps (anti-embolic pumps)-calf/thigh
DVT boots-calf/thigh
EPC cuffs/ stockings-External pneumatic compression-calf/thigh
Intermittent pneumatic compression stockings
Intermittent compression device (ICD)
Leg pumpers
Pneumatic intermittent impulse compression device
Rapid inflation asymmetrical compression (RIAC) devices
Sequential compression device
Sequential pneumatic hose
Thrombus pumps-calf/thigh
Venous Foot Pump (VFP) AE pumps-foot only
Foot pump
Plantar venous plexus pump-foot only
SC boots-foot only
SCD boots-foot only
Venous foot pump
Note: This table is not meant to be an inclusive list of all available prophylaxis; rather it represents current information available at the time of publication.

1 The U.S. Food and Drug Administration (FDA) has approved Eliquis (apixaban) to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation or to reduce the risk of blood clots, deep vein thrombosis (DVT) and pulmonary embolism (PE) following knee or hip replacement surgery only. It is additionally approved for treatment of DVT and PE and for the reduction in the risk of recurrent DVT and PE following initial therapy.
2 The U.S. Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce the risk of blood clots, deep vein thrombosis (DVT) and pulmonary embolism (PE) following knee or hip replacement surgery only. It is additionally approved: to reduce the risk of stroke in patients with non-valvular atrial fibrillation; for treatment of DVT or PE; to reduce the risk of recurrent DVT and PE following initial treatment.
3 The FDA approved edoxaban (Savaysa) to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem. Savaysa has been approved to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have already been treated with anti-clotting drug administered by injection or infusion (parenterally), for five to ten days.

Table 2.6 Qualifiers and Modifiers Table

Note: These guideleines apply only to those data elements that refer to them in their Guidelines for Abstraction Exclusion list(s)

Qualifiers Modifiers
Qualifiers are words used as adjectives to indicate some uncertainty about whether or not a condition really exists. Quantitative modifiers are adjectives that quantitatively describe a condition
The following qualifiers should be abstracted as negative findings , unless otherwise specified - Consider this list all-inclusive:
  • And/or (+/-; e.g., "ST abnormalities consistent with ischemia and/or injury"), except when comparing only inclusions (e.g., "ST segment elevation and/or STEMI")
  • Cannot exclude
  • Cannot rule out
  • Could/may/might be
  • Could/may/might have
  • Could/may/might have been
  • Could/may/might have had
  • Could/may/might indicate
  • Or, except when comparing only inclusions
  • Possible
  • Questionable (?)
  • Risk of
  • Rule out (r'd/o, r/o'd)
  • Suggestive of
  • Suspect
  • Suspicious
  • Vs., except when comparing only inclusions
    Example: If the in-hospital echocardiogram report documents "questionable LVSD", this should be abstracted as a negative finding.
The following quantitative modifiers should be abstracted as negative findings , unless otherwise specified - Consider this list all-inclusive:
  • Borderline
  • Insignificant/not significant/no significant
  • Minor
  • Scant
  • Slight
  • Sub-clinical
  • Subtle
  • Trace
  • Trivial

Table 2.7 Anticoagulation Therapy Table

Anticoagulation Therapy – All Inclusive Inclusion/Synonyms
Direct Thrombin Inhibitors Acova
Angiomax
Angiox
Argatroban
Bivalirudin
Dabigatran
Dabigatran etexilate
Lepirudin
Pradaxa
Recombinant Hirudin
Refludan
Glycoprotein IIb/IIIa Inhibitor: Abciximab
Aggrastat
Eptifibatide
Integrilin
ReoPro
Tirofiban


Related Topics

Related Topics

Appendix HTJC
Specifications Manual for Joint Commission National Quality Measures (v2016A)
Discharges 07-01-16 (3Q16) through 12-31-16 (4Q16)
^